
Moderna, AbbVie, CG Oncology, Natera, and Amgen are the five Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks are shares of companies that use biological science to develop or produce medicines, vaccines, diagnostics, and other health-related products. For investors, they can offer growth potential but often carry higher risk because a company’s prospects may depend on clinical-trial results, regulatory approvals, and funding needs. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.
Moderna (MRNA)
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Shares of MRNA traded down $6.69 on Monday, reaching $216.68. 2,604,532 shares of the stock traded hands, compared to its average volume of 12,527,954. The firm has a market cap of $87.67 billion, a price-to-earnings ratio of -30.52 and a beta of 1.16. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.62 and a quick ratio of 3.47. Moderna has a 12 month low of $22.28 and a 12 month high of $280.80. The stock’s 50-day moving average price is $201.67 and its 200-day moving average price is $96.41.
Read Our Latest Research Report on MRNA
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Shares of ABBV stock traded up $1.74 during mid-day trading on Monday, reaching $296.77. The company’s stock had a trading volume of 1,265,175 shares, compared to its average volume of 6,274,974. AbbVie has a 1-year low of $190.75 and a 1-year high of $302.93. The company has a market cap of $524.58 billion, a P/E ratio of 51.12, a PEG ratio of 1.34 and a beta of 0.20. The firm’s 50-day moving average is $275.51 and its two-hundred day moving average is $240.91.
Read Our Latest Research Report on ABBV
CG Oncology (CGON)
CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.
CGON traded up $9.32 during midday trading on Monday, reaching $83.72. 4,343,685 shares of the company’s stock were exchanged, compared to its average volume of 1,117,540. The business has a 50-day simple moving average of $68.04 and a two-hundred day simple moving average of $66.54. The firm has a market capitalization of $7.48 billion, a price-to-earnings ratio of -30.03 and a beta of 0.35. CG Oncology has a one year low of $37.01 and a one year high of $93.95.
Read Our Latest Research Report on CGON
Natera (NTRA)
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
NASDAQ:NTRA traded down $24.86 during trading hours on Monday, reaching $294.23. The company had a trading volume of 781,905 shares, compared to its average volume of 1,464,034. The stock has a 50-day moving average of $379.70 and a two-hundred day moving average of $271.61. Natera has a one year low of $181.00 and a one year high of $437.41. The firm has a market capitalization of $42.66 billion, a PE ratio of -259.39 and a beta of 1.55.
Read Our Latest Research Report on NTRA
Amgen (AMGN)
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
AMGN stock traded up $2.71 during trading on Monday, hitting $468.38. 431,964 shares of the stock traded hands, compared to its average volume of 2,742,081. Amgen has a one year low of $312.39 and a one year high of $483.99. The stock has a market cap of $253.35 billion, a price-to-earnings ratio of 27.17, a P/E/G ratio of 3.24 and a beta of 0.43. The company has a 50 day simple moving average of $425.31 and a 200 day simple moving average of $381.17. The company has a current ratio of 1.48, a quick ratio of 1.20 and a debt-to-equity ratio of 3.60.
Read Our Latest Research Report on AMGN
Further Reading
- MarketBeat’s Top Five Stocks to Own in November 2026
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
- Embraer’s Record Backlog Looks Promising, But Can It Keep Its Margins Climbing?
- Could Big Buybacks Be the Next Catalyst for These 3 AI Stocks?
- Sandisk’s Sell-Off May Be Losing Steam, But the Biggest Risk Still Looms
- Meta’s Access to Capital Remains Strong, But Borrowing Is Becoming More Expensive
